Why ResApp Health Ltd (ASX:RAP) shares rocketed higher today

The ResApp Health Ltd (ASX: RAP) share price has continued its strong run today and rocketed 20% higher to 21.5 cents.

This means the healthcare technology company’s shares have now risen by around 65% in the space of a month.

Why have ResApp’s shares rocketed higher?

This morning the company added to its recent positive news flow by announcing that it has partnered with Lockheed Martin in the Defense Advanced Research Projects Agency (DARPA) Warfighter Analytics using Smartphones for Health (WASH) program.

According to the release, the WASH program will build a software suite to predict warfighter readiness and potential chronic and acute illness in a variety of contexts using only a standard cell phone instead of other specialized, expensive medical devices.

The company’s CEO and managing director, Tony Keating, appeared to be pleased with this latest development. He commented that: “We are delighted to be working with Lockheed Martin to develop audio signatures and algorithms as key components in products to support the mission readiness and health of United States military personnel.”

No financial terms were disclosed in today’s announcement.

Should you invest?

Last year things looked incredibly bleak for the company following the failure of its Smartcough-c study. But I must admit to being very impressed at the company’s turnaround in 2018.

However, there certainly is a lot riding on the new Smartcough-c2 study results. The company has insisted that the first study failed due to the poor quality of the audio recordings.

Whereas this time around things appear to be going much more smoothly and only 3% of recordings were unacceptable at its last update.

The results of the study are due to be released later this month. I would suggest investors keep their powder dry until their release and focus on other options in the meantime.

Healthcare technology shares such as Pro Medicus Limited (ASX: PME) and Volpara Health Technologies Ltd (ASX: VHT) could be quality alternatives. Incidentally, Pro Medicus delivered a strong result today.

The ASX small cap healthcare share up 285% with no sign of stopping...

One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...

To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended PRO Medicus Ltd. and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.